抗RNP,抗Sm抗体の臨床的研究 第2編 全身性エリテマトーデスに認められる中枢神経症状の臨床免疫学的研究 ―抗RNP抗体との関連において―

機関リポジトリ

書誌事項

タイトル別名
  • Clinical studies on anti-RNP and anti-Sm antibodies Part 2. Clinical and serological study of central nervous system disease in patients with systemic lupus erythematosus, and the relationship to antibodies of ribonucleoprotein

この論文をさがす

説明

Forty of 150 (27%) patients with systemic lupus erythematosus (SLE) had central nervous system (CNS) disease including psychosis (24), seizure (10), coma (2), meningitis (3) and blindness (1). Raynaud's phenomenon (60%) and antibody to ribonucleoprotein (RNP) (78%) were significantly more common in the CNS SLE group than non-CNS SLE group. On the contrary, LE cell (40%) and clinical renal disease (43%) were less common in the CNS SLE group than the non-CNS SLE group. At the onset of CNS disease, the incidence of elevated n-DNA binding (35%) and decreased CH50 (35%) were significantly lower than in patients without CNS disease. Anti-RNP was present in 78% of the patients at the onset of CNS disease and 47% of the patients without CNS disease; this difference was significant (p<0.002). Anti-RNP in CSF was demonstrated by the precipitin reaction in 7 patients at the onset of CNS disease. Anti-Sm in CSF was found in only one patient with CNS disease. Enrichment of anti-RNP in CSF over the serum level was demonstrated in 3 patients. Seventy percent of the CNS episodes began within 8 weeks of the initiation or increase in dose of corticosteroids, including 9 patients within the 1st week, 9 during the 2nd week, 2 during the 3rd week, 5 during the 4th week and 3 during the 5th to 8th week. These data suggest a high incidence of CNS episodes in patients with SLE and anti-RNP after increasing the corticosteroid dosage.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ